Experimental antibody trio takes on Hard-to-Treat melanoma

NCT ID NCT06784648

Ongoing Disease control Sponsor: BioInvent International AB Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new experimental antibody called BI-1607 alongside two existing immunotherapies (ipilimumab and pembrolizumab) in 35 people with advanced melanoma that has spread or cannot be removed. The goal is to see if the combination is safe and can shrink tumors. The study is currently active but not recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI-1607 (an experimental antibody) combined with ipilimumab and pembrolizumab (immunotherapies)
What this could lead to: If successful, this combination could improve the immune system's ability to fight advanced melanoma that has stopped responding to current treatments.
What could go wrong: This is an early-phase trial with only 35 participants, so results may not apply broadly. The added drug may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma Neoplasm Metastasis uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA MELANOMA BRAF V600E/K MUTATED MELANOMA METASTATIC MELANOMA NEGATIVE FOR BRAF MELANOMA NEGATIVE FOR NRAS MELANOMA OF SKIN MELANOMA RECURRENT MELANOMA STAGE III OR IV MELANOMAS UVEAL MELANOMA, METASTATIC

Contacts and locations

Locations

Charité - Universitatsmedizin Berlin

Berlin, Germany
Hospital Universitario Vall d'Hebron

Barcelona, Spain
Sarah Cannon Research Institute UK

London, Greater London, W1G 6AD, United Kingdom
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
University Hospital 12 de Octubre

Madrid, Spain
University Hospital Essen

Essen, Germany
University Hospital Heidelberg

Heidelberg, Germany
University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg and Clinical Cooperation Unit Dermato-Oncology(G300) German Cancer Research Center(DKFZ)

Mannheim, Germany
Velindre Cancer Centre

Cardiff, Wales, CF14 2TL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.